Rockwell Medical (NASDAQ:RMTI) Earns “Buy” Rating from HC Wainwright

Rockwell Medical (NASDAQ:RMTI)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $7.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 236.54% from the stock’s current price.

RMTI has been the topic of several other research reports. StockNews.com cut Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Friday. RODMAN&RENSHAW raised shares of Rockwell Medical to a “strong-buy” rating in a report on Thursday, November 14th. Finally, Rodman & Renshaw began coverage on shares of Rockwell Medical in a report on Thursday, November 14th. They set a “buy” rating and a $5.00 price objective for the company.

Rockwell Medical Trading Up 1.5 %

NASDAQ:RMTI opened at $2.08 on Monday. Rockwell Medical has a 52 week low of $1.16 and a 52 week high of $5.15. The firm has a 50-day moving average price of $2.89 and a two-hundred day moving average price of $2.71. The firm has a market cap of $67.22 million, a price-to-earnings ratio of -41.60 and a beta of 1.38. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.00 and a current ratio of 2.41.

Institutional Investors Weigh In On Rockwell Medical

Large investors have recently added to or reduced their stakes in the company. Armistice Capital LLC boosted its position in Rockwell Medical by 22.5% during the second quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock worth $5,670,000 after purchasing an additional 592,000 shares during the period. XTX Topco Ltd boosted its holdings in Rockwell Medical by 45.7% in the 3rd quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock worth $113,000 after buying an additional 8,922 shares during the period. Renaissance Technologies LLC grew its stake in Rockwell Medical by 877.1% in the 2nd quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock valued at $181,000 after buying an additional 92,189 shares in the last quarter. Beacon Financial Advisory LLC bought a new stake in Rockwell Medical during the 3rd quarter valued at $98,000. Finally, Walleye Capital LLC purchased a new stake in shares of Rockwell Medical during the third quarter worth $435,000. Hedge funds and other institutional investors own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.